FDA inspection
Hydro Med Inc: FDA inspection ending May 1, 2002
FDA inspection 215217 · Sherman Oaks, CA
Key facts
| Inspection ID | 215217 |
|---|---|
| Firm | Hydro Med Inc |
| FEI number | 2020265 |
| Address | 4419 van Nuys Blvd Ste 310 |
| City | Sherman Oaks |
| State | CA |
| ZIP | 91403-5737 |
| Fiscal year | 2002 |
| Inspection end date | May 1, 2002 |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data